Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of ZYPREXA and ZYPREXA VELOTAB in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ZYPREXA and ZYPREXA VELOTAB, as with all other anti-psychotics (including first generation anti-psychotics), provide a moderate Improvement in Actual Benefit (IAB III) in the treatment of schizophrenia. |
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
UksHMXRJhCZhWBUE
